FIELD: pharmaceuticals.
SUBSTANCE: invention refers to a compound of formula I or its pharmaceutically acceptable salt. In formula IX is sulfur or oxygen; Z1 and Z2 are identical or different and each independently represents nitrogen or CH; R1 denotes NR3R4, wherein said R3 and R4 each independently denotes H, C1-6 alkyl, substituted C1-6 alkyl, C3-7 cycloalkyl, substituted C3-7 cycloalkyl or heterocycle, R2 represents H or halogen; wherein substituted C1-6 alkyl is C1-6 alkyl substituted with one or more substituents, selected from the group consisting of C1-3 alkyl, optionally having from one to three fluorine substitutes, amino, aryl, heteroaryl, heterocycle and halogen; substituted C3-7 cycloalkyl is C3-7 cycloalkyl, substituted with one substitute selected from aryl; aryl is phenyl, optionally substituted with one or more substitutes selected from a group consisting of substituted C1-3 alkyl, optionally having from one to three fluorine substitutes, heteroaryl, heterocycle, aryl, C1-3 alkoxy, optionally having from one to three fluoro substitutes, aryloxy, acyloxy, carboxy, amino, cyano and halogen; heteroaryl is benzoimidazolyl, furanyl, imidazopyridinyl, indolyl, oxazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidyl, thiophenyl, tetrazolyl or thiazolyl, optionally substituted with one or more substitutes selected from C1-3 alkyl; and the heterocycle is piperidinyl, piperazinyl or morpholinyl; or a compound selected from the group given in the claim. Invention also relates to a pharmaceutical composition, to a method for preventing, relieving the severity or treating a condition, to a method for antagonizing the A3-adenosine receptor.
I
EFFECT: technical result is obtaining novel compounds of formula I, which have the properties of the antagonist of the A3-adenosine receptor and are useful in treating glaucoma.
10 cl, 5 tbl, 244 ex
Title | Year | Author | Number |
---|---|---|---|
IMIDAZOPYRROLOPYRINE DERIVATIVES USEFUL FOR TREATING DISEASES CAUSED BY ABNORMAL ACTIVITY OF PROTEIN KINASES JAK1, JAK3 OR SYK | 2010 |
|
RU2711869C2 |
IMIDAZOPYRROLOPYRAZINE DERIVATIVES, USEFUL FOR TREATMENT OF DISEASES, CAUSED BY ABNORMAL ACTIVITY OF PROTEINKINASES Jak1, Jak3 OR Syk | 2010 |
|
RU2570416C2 |
TRICYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USING THEM FOR TREATING IMMUNOLOGICAL AND ONCOLOGICAL COMPOUNDS | 2009 |
|
RU2545023C9 |
HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
COMPOUND WITH ANTI-CANCER ACTIVITY | 2019 |
|
RU2809763C2 |
BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2018 |
|
RU2776846C2 |
TRICYCLIC NITROGEN-CONTAINING DERIVATIVES OF IMIDAZO[4,5-C]PYRIDINE, HAVING INHIBITING ACTIVITY IN RESPONSE TO HYSTAMINE 4 RECEPTOR (HH4R) | 2012 |
|
RU2628074C2 |
MACROCYCLIZATION REACTIONS AND INTERMEDIATE COMPOUNDS AND OTHER FRAGMENTS SUITABLE FOR PREPARING ANALOGUES OF HALICHONDRIN B | 2014 |
|
RU2710545C2 |
METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
Authors
Dates
2020-11-25—Published
2017-01-13—Filed